Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.

@article{Parodi2010ImpactOB,
  title={Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.},
  author={Guido Parodi and David Antoniucci and Eugenia Nikolsky and Bernhard Witzenbichler and Giulio Guagliumi and Jan Zbigniew Peruga and Thomas A Stuckey and Darius Dudek and Ran Kornowski and Franz Hartmann and Alexandra J Lansky and Roxana Mehran and Gregg Whitney Stone},
  journal={JACC. Cardiovascular interventions},
  year={2010},
  volume={3 8},
  pages={796-802}
}
OBJECTIVES This study sought to assess the relationship between 1-year mortality and baseline patient risk in the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. BACKGROUND The HORIZONS-AMI trial showed that bivalirudin compared with unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) decreased major bleeding and 30-day and 1-year mortality in patients undergoing primary percutaneous intervention for acute… CONTINUE READING